NCT00829231View on ClinicalTrials.gov

Hepatic Impairment Study

PHASE1CompletedINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions

Liver Disease

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Mildly Hepatic Impaired Subjects

DRUG

Sorafenib (Nexavar, BAY43-9006)

Moderately Hepatic Impaired Subjects

DRUG

Sorafenib (Nexavar, BAY43-9006)

Healthy Subjects

Trial Locations (3)

32809

Orlando

33014

Miami

37920

Knoxville

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY